A T-cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers, according to new research.
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary.
The FDA asked the manufacturer of ponatinib (Iclusig) to suspend marketing and sales of the drug, hydrocodone bitartrate extended-release capsules (Zohydro ER) gained FDA approval, and other FDA actions.
A new combination of a poly ADP-ribose polymerase (PARP) inhibitor drug and conventional platinum-based chemotherapy may extend the lives of women with ovarian cancer, according to a new study.
This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|